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Abstract
Background: Bovine dialyzable leukocyte extract (bDLE) is derived from immune leukocytes obtained from bovine
spleen. DLE has demonstrated to reduce transcription of Human Immunodeficiency Virus Type 1 (HIV-1) and inactivate
the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) signaling pathway. Therefore, we decided to
clarify the mode of antiviral action of bDLE on the inhibition of HIV-1 infection through a panel of antiviral assays.
Results: The cytotoxicity, HIV-1 inhibition activity, residual infectivity of bDLE in HIV-1, time of addition experiments,
fusion inhibition of bDLE for fusogenic cells and the duration of cell protection even after the removal of bDLE
were all assessed in order to discover more about the mode of the antiviral action.
HIV-1 infectivity was inhibited by bDLE at doses that were not cytotoxic for HeLa-CD4-LTR-b-gal cells. Pretreatment
of HIV-1 with bDLE did not decrease the infectivity of these viral particles. Cell-based fusion assays helped to
determine if bDLE could inhibit fusion of Env cells against CD4 cells by membrane fusion and this cell-based fusion
was inhibited only when CD4 cells were treated with bDLE. Infection was inhibited in 80% compared with the
positive (without EDL) at all viral life cycle stages in the time of addition experiments when bDLE was added at
different time points. Finally, a cell-protection assay against HIV-1 infection by bDLE was performed after treating
host cells with bDLE for 30 minutes and then removing them from treatment. From 0 to 7 hours after the bDLE
was completely removed from the extracellular compartment, HIV-1 was then added to the host cells. The bDLE
was found to protect the cells from HIV-1 infection, an effect that was retained for several hours.
Conclusions: bDLE acted as an antiviral compound and prevented host cell infection by HIV-1 at all viral life cycle
stages. These cell protection effects lingered for hours after the bDLE was removed. Interestingly, bDLE inhibited fusion
of fusogenic cells by acting only on CD4 cells. bDLE had no virucidal effect, but could retain its antiviral effect on target
cells after it was removed from the extracellular compartment, protecting the cells from infection for hours.
bDLE, which has no reported side effects or toxicity in clinical trials, should therefore be further studied to determine its
potential use as a therapeutic agent in HIV-1 infection therapy, in combination with known antiretrovirals.
Background
The pandemic of Human Immunodeficiency Virus Type 1
(HIV-1) infection, the cause of Acquired Immunodefi-
ciency Syndrome (AIDS), is a grave public health issue
and ranks among the greatest infectious disease scourges
in history [1]. There were more than 33.3 million people
worldwide with HIV-1 infection or AIDS, according to the
latest estimates by the Joint United Nations Program on
HIV/AIDS (UNAIDS) [2].
The use of highly active antiretroviral therapies has
dramatically reduced morbidity and mortality among
patients infected with HIV-1 [3,4]. However, the success
of antiretroviral treatment is frequently restricted by the
emergence of HIV-1 drug resistance [5]. Therefore, the
search for new drugs to inhibit viral replication [6] or to
restore the immune system in HIV-1 patients continues.
Newly discovered naturally derived or chemically synthe-
sized substances are continuously being evaluated as
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therapeutic drug candidates with antiviral activity. These
potential drugs are eagerly awaited and may prove benefi-
cial for the growing number of HIV-infected individuals
who have developed resistance to the currently available
antiretrovirals [7].
Dialyzable Leukocyte Extract (DLE) is derived from
immune leukocytes and contains low molecular weight
proteins (< 10, 000 Da) [8]. DLE possess three chromato-
graphic fractions (Fa, Fb and Fc), Fraction Fb inhibits
viral production more than 80%. Therefore, fractions Fa
and Fc did not show inhibitory effect for any viral dose
used [9].
This preparation is a modulator of the immune response
that is able to transmit the ability to express delayed-type
hypersensitivity (DTH) and cell mediated immunity (CMI)
from sensitized donors to immune deficient recipients
[10]. DLE also mediates effects on immune system func-
tions, further influencing its response. These effects
include cytokine modulation [11,12], the activation of
monocyte and macrophage chemotaxis [13] and natural
killer activity enhancement [14]. The therapeutic and pro-
phylactic applications have been the most important and
interesting aspects of DLE [15], principally because there
has been no reported side effects or toxicity in humans
[16].
DLE has demonstrated to be effective in those diseases
in which Cell-Mediated Immunity (CMI) plays a relevant
role in protection against and control of the disease, such
as viral infections ((herpes zoster [17], hepatitis B [18],
intracellular bacterial diseases like tuberculosis [19] and
leprosy [20], parasite infections, such as leishmaniasis [21]
or cryptosporidiosis [22], and fungal infections (mucous-
cutaneous candidiasis [23]), as well as in primary immuno-
deficiencies (Wiskott Aldrich syndrome [24], Behçet’s syn-
drome [25]), bronchial asthma [26], otitis media [27],
uveitis [28]) and some types of cancer [29,30].
Previously we reported that bovine DLE (bDLE) was
useful as an adjuvant in breast cancer patients under-
going chemotherapy, demonstrating protective effects
against myelosuppression secondary to antitumoral drugs
by improving cellular and humoral immunity, as well as
in regulating the production of different cytokines
involved in cellular proliferation [16,29,30]. Furthermore,
in vitro assays demonstrated that bDLE affected the regu-
lation of the expression of p53, bab-1, c-myc, bax, bcl-2
and bad mRNA [31,32]. Nowadays, the majority of the
studies on DLE are limited to diseases that occur with
chronic inflammation [33], like HIV-1 infection.
A main feature of HIV infection is the expression of
several proinflammatory cytokines expressed as soluble
factors or membrane-bound molecules that regulate both
HIV replication and T cell apoptosis. Proinflammatory
cytokines have key roles in the HIV lifecycle, especially at
the level of transcription, by enhancing the ability of HIV
to establish latent reservoirs on HIV infected patients. In
addition, several HIV proteins, such as Nef, Tat, and Vpr
hijack proinflammatory cytokine signaling, further under-
lining the potential importance of inflammation in HIV
pathogenesis. Moreover, an in vivo chronic inflammatory
state has been correlated to increased levels of viremia
and accelerated disease progression [34]. DLE has been
used to treat HIV-1 infected patients, either asympto-
matic or at the AIDS phase, resulting in a partial immune
reconstitution [35,36], a lower incidence of opportunistic
infections [37], and clinically relevant improvement
[16,38].
Viruses have evolved to modulate the NF-kB pathway
to enhance viral replication, improve host cell survival,
and evade the immune response [39]. With HIV, viral
and cellular membrane fusion activates NF-B, a process
that requires CD4+ T cells. HIV-1 contains regulatory
regions in its long terminal repeat (LTR) implicated in
the control of viral gene expression that contain three
Sp1 core promoter binding sites and two NF-B core
enhancer motifs [40] that are recognized by endogenous
host cell transcription factors. These are important regu-
latory elements in the LTR that control expression of the
promoter along with Tat, a viral transactivator protein
necessary for HIV-1 replication [41].
Previous studies have reported DLE in vitro reduced
HIV-1 transcription [42] by regulating activation of NF-B
and Sp1 transcription factors [42-44]. Other studies
reported DLE induced the production of leukocytes and
reduced TNF-a [44] and TFG-b1 [45] secretion, which are
cytokines that play a pivotal role in HIV-1 pathogenesis by
up-regulating the transcription of HIV-1 and increasing
the expression of HIV co-receptor CXCR4, respectively.
Additionally, envelope glycoprotein gp120 can signal NF-
B by engaging the CD receptor in a pathway that involves
p56 and activates NF-B and HIV-1 LTR transcription
[46]. HIV-1 gene expression and transcription is an essen-
tial step in the viral life cycle and is considered to be a
possible target for the inhibition of HIV-1 replication [43].
The exact mechanism of action of bDLE is still unclear,




The half cytotoxic concentration (CC50) of bDLE when
exposed to HeLa-CD4-LTR-b-gal cells was 3.41 ± 0.1 IU
(P < 0.0001) (Figure 1A).
Range of antiviral activity
bDLE was tested against an HIV-1IIIB isolate using indi-
cator cells in which infection was quantified by a lucifer-
ase-based assay. The concentration of bDLE at which
HIV-1IIIB infectivity was inhibited by 50% (IC50) was
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found to be 1.53 ± 0.1 IU (P < 0.0001) (Figure 1B). In
addition, bDLE inhibited HIV-1IIIB infectivity at doses
that were not cytotoxic for HeLa-CD4-LTR-b-gal cells.
The therapeutic index (TI = CC50/IC50) for bDLE in
these cells was then calculated to be 2.23. The therapeu-
tic index reflects a compound’s overall efficacy by relating
cytotoxicity (CC50) with effectiveness, measured as the
ability to inhibit infection (IC50), under the same assay
conditions.
Virucidal activity
To determine if the bDLE might have effects on the
virus itself, HIV-1IIIB isolates were treated with different
concentrations of bDLE. After removal of bDLE, the
residual infectivity of the cell-free viruses was quantified
by a luciferase-based assay. As shown in Figure 2, bDLE
pretreatment of HIV-1IIIB did not decrease the infectiv-
ity of the viral particles in a dose dependent manner.
Inhibition of Env/CD4-mediated membrane fusion
A cell-based fusion assay was used to mimic the gp120-
CD4-mediated fusion process of HIV-1 with bDLE.
When bDLE was exposed first to the CD4 cells-Env cells
mixture, fusion between both cells was blocked in a
dose-dependent manner. Cell-based fusion was also
inhibited when bDLE was applied only to CD4 cells for
30 minutes, followed by bDLE removal. However, when
Env cells were first exposed to bDLE for 30 minutes,
then removed and added to CD4 cells, fusion between
both cells was not inhibited (Figure 3A). Known
antiretroviral drugs, such as UC781 (NNRTI), were used
as controls in this cell based fusion assay and did not
inhibit cell fusion (Figure 3B). T-20 (Fusion Inhibitor),
did inhibit cell fusion in all assays, however, except when
exposed to CD4 cells for only 30 minutes and then
removed, after which the cells were mixed (Figure 3C).
Figure 1 Cytotoxicity assessment of bDLE and HIV-1 inhibition activity. A) HeLa-CD4-LTR-b-gal cells (5 × 104 cells/well) and B) HIV-1IIIB cell-
free viruses (MOI 0.2-0.5) were challenged with two-fold serial dilutions of bDLE. Cell viability and b-gal activity were measured with a luciferase-
based assay 24 h after nanosilver exposure. Percentage values are relative to the positive control (no compound treatment). The data represent
the means ± standard deviations from three separate experiments, each of which was carried out in duplicate.
Figure 2 Residual activity in HIV-1 strains. HIV-1IIIB cell-free
viruses were exposed to serial dilutions of bDLE for 5 minutes. The
viruses were then ultracentrifuged, washed twice and added to
HeLa-CD4-LTR-b-gal cells. After 24 hours, b-gal activity was
measured. Percentage values are relative to the positive control
(infected cells without bDLE treatment). The data represent the
means ± standard deviations from three separate experiments, each
of which was carried out in duplicate.
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Time (Site) of Intervention
To further determine the antiviral target of bDLE, a time-
of-addition experiment was performed using a single
cycle infection assay. The time-of-addition experiment
was used to determine the stage(s) of the viral life cycle
that were blocked by bDLE. Several antiretroviral drugs
were chosen as controls as they mark different stages of
the viral cycle (i.e., fusion or entry, retrotranscription,
protease activity, and integration into the genome). As
seen in Figure 4(A-E), the antiviral activity of T-20,
UC781, 118-D-24 and Amprenavir started to decline
after the cycle stage that they targeted was passed. The
fusion inhibitor’s activity declined after 2 h (Figure 4B),
the RT inhibitor after 8 h (Figure 4C), the integrase inhi-
bitor after 18 h (Figure 4D) and the protease inhibitor
after 15-18 h (Figure 4E). In contrast, bDLE retained its
antiviral activity up to 48 h (Figure 4A) after the HIV
inoculation, inhibiting HIV-1 infection in 80% of infected
cells against the positive control.
Cell protection assays
HeLa-CD4-LTR-b-gal cells were pretreated with bDLE for
30 minutes, which was then removed from the extracellu-
lar compartment with three washes, and subsequently the
HeLa-CD4-LTR-b-gal cells were exposed to HIV-1IIIB for
different pretreatment times (1, 5, 7, 10, 24 and 48 hours).
As shown in Figure 5, HIV-1 infection was inhibited, as
host cells were protected even after 7 hours from the
bDLE removal.
Discussion
Due to the DLE immunomodulatory properties dis-
cussed before, progression to AIDS in asymptomatic
HIV-1 infected individuals treated with conventional
Figure 3 Inhibition of Env/CD4-mediated membrane fusion. b-gal activity was measured after CD4 cells and Env cells were co-cultured after
exposure to A) bDLE, B) UC781 and C) T-20 under different circumstances: (■) CD4 cells were exposed to the compound and co-cultured with
Env cells for 24 hours; (▲) CD4 cells were exposed to the compound for 30 minutes, washed, and co-cultured with Env cells for 24 hours; (✘)
Env cells were exposed to the compound for 30 minutes, washed, and co-cultured with CD4 cells for 24 hours. Percentage values are relative to
the positive control (cell-to-cell fusion without pretreatment with drug). The data represent the means ± standard deviations from three separate
experiments, each of which was carried out in duplicate.
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anti-retrovirals, has shown a retarded progression to
AIDS under adjuvant treatment with dialyzable leuko-
cyte extract (DLE), demonstrated by lower incidences of
opportunistic infections and improved cellular immunity
[9,38,44]. DLE simultaneously shows anti-HIV activity
[44,47,48], modulates different types of immune effec-
tors (e.g., cytokines and transcription factors)[11,47,49]
and restores leukocyte subsets in treated patients
[16,29,35,37]. All these properties make DLE a potential
drug to be used in a therapeutic combination with anti-
retrovirals to improve immune and clinical responses.
Bovine dialyzable leukocyte extract (bDLE) is defined
as the dialyzate of a heterogeneous mixture of low mole-
cular weight substances released from disintegrated
blood leukocytes or lymphoid tissue obtained from
homogenized bovine spleen. Previous studies have
shown inhibition of HIV-1 infection by suppression of
the activity of essential transcription factors [42-44] and
cytokines by DLE. The purpose of this study was to
demonstrate the mechanism of antiviral action of bDLE
in vitro in the inhibition of HIV-1 and the protection of
host cells from infection.
First, we compared the half cytotoxic concentration of
bDLE when exposed to HeLa-CD4-LTR-b-gal cells
(CC50 = 3.41 IU) (Figure 1A) with the concentration of
bDLE at which HIV-1IIIB infectivity was inhibited by
50% (IC50 = 1.33 IU) (Figure 1B) [48]. Then, the thera-
peutic index was determined (TI = 2.56) and used as an
indicator of bDLE overall efficacy and safety. Despite
Figure 4 Time of intervention in HIV-1 life cycle. HeLa/CD4-LTR-b-gal cells were infected with HIV-1IIIB cell-free virus before A) bDLE (2 IU), B) T-20 (100
μM), C) UC781 (70 nM), D) 118-D-24 (120 μM) and E) Amprenavir (0.1 mM), were added upon HIV-1 inoculation (time zero) or at various time points post-
infection. b-gal activity was measured following 24 hr of incubation. Percentage values are relative to the positive control (infected cells without drug
pretreatment). The data represent the means ± standard deviations from three separate experiments, each of which was carried out in duplicate.
Figure 5 Cell protection against HIV-1 infection. b-gal activity was
measured after HeLa/CD4-LTR-b-gal cells were exposed to bDLE (2
IU) for 30 minutes, washed and exposed to HIV-1IIIB cell-free virus at
various time points post-treatment. Percentage values are relative to
the positive control (infected cells without drug pretreatment). The
data represent the means ± standard deviations from three separate
experiments, each of which was carried out in duplicate.
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the fact that TI was lower than expected (< 10), bDLE is
a compound that has been used in clinical assays for
more than fifty years without adverse reactions [10].
Better understanding of its inhibition mechanism can
contribute to the development of new and improved
anti-HIV-1 agents, which could be more efficient and
have lower cytotoxicity. Furthermore, the residual infec-
tivity [50,51] of cell-free viruses after bDLE treatment
showed no inhibitory activity (Figure 2), which suggests
that bDLE does not act as a virucide on the viral mem-
brane to inhibit infection. bDLE showed inhibition of
fusogenic cell-cell interactions in a dose-dependent
manner when bDLE was exposed to CD4 cells, bDLE
was then removed and the CD4 cells were mixed with
Env cells. However, after 30 minutes pretreatment of
Env cells with bDLE and then transfer to CD4 cells,
there was no inhibition of Env-CD4 cell fusion. This
observation further supported our previous results that
bDLE acted on CD4 expressing cells and not on the Env
of the HIV-1 virus. Furthermore, when exposed to CD4
cells for only 30 minutes, which is the time required for
conformational changes in gp120 after CD4 binding
[52], bDLE again showed inhibition in a dose-dependent
manner (Figure 3A). These data suggested that bDLE
acted on CD4 cells to inhibit HIV-1 infection. Antiviral
results reported by Fernandez-Ortega et al. [53,54] have
also contributed to the knowledge of the molecular
mechanisms responsible for the effectiveness of bDLE
against HIV infection.
To further determine the antiviral target of bDLE, a
time-of-addition experiment was used to define the stage
(s) of the viral life cycle that are blocked by these com-
pounds. These results were compared with several antire-
troviral drugs as controls that marked different stages of
the viral cycle [55-61] (Figure 4B-E). Our findings sug-
gested that bDLE highly inhibited HIV-1 infection at all
stages (Figure 4A), possibly due to viral Tat protein
down-regulation (Tat activates b-galactosidase indicator
gene expression in HeLa-CD4-LTR-b-gal cells). Inhibi-
tion of HIV-1 Tat activity correlates with down-regula-
tion of bcl-2 [62], but the action of bDLE on bcl-2 has
not yet been determined in HIV-1 studies. Previously,
bcl-2 was found to be reduced in breast cancer cell lines
when treated with bDLE [32]. Furthermore, DLE inacti-
vated the NF-B signaling pathway by reducing the
secretion of cytokines, such as IL-1 and TNF-a, which
are effective inducers of NF-B activity [63]. In HIV-
infected T cells, NF-B-dependent transactivation is
essential for HIV-LTR induction. Interestingly, even the
function of HIV Tat in resting CD4 T lymphocytes
depends on B responsive elements in the LTR [46].
Based on these interesting findings, it will be necessary to
focus specifically on the transcriptional factors (NF-B
and SP1) and pro-apoptotic genes (bcl-2) in future
research on bDLE as an antiviral against HIV-1 infection.
Lastly, bDLE was capable of rendering CD4 expressing
cells resistant against HIV-1 infection by residual active
virus for several hours [64]. Previous results indicated that,
although pretreatment of cells (MT-4) with DLE for 3
hours had no effect, inhibition of HIV-1 production was
observed when cells were pre-treated for a longer period
of time (from 1 to 7 days), an effect that was characterized
by the decline in TNFa and TGFb1 gene expression and
inhibition of transcriptional factors [9]. In our assays, after
pretreatment of the HeLa-CD4-LTR-b-gal cells and bDLE
removal prior to viral challenge, protection against infec-
tion lasted 7 hours after bDLE was removed from the
extracellular compartment (Figure 5). These results indi-
cated that bDLE could induce long-term viral inhibition
through cell protection, as well as modulate cell suscept-
ibility to viral infection in vitro, in agreement with pre-
viously reported data on DLE obtained from human
donors by molecular methods [9].
Conclusion
The data presented here were novel in that they proved
that bDLE acted by inhibiting HIV-1 infection through
protection of the host target CD4 cells at noncytotoxic
levels. This effect was found to be modulated through
transcriptional factors (NF-B and SP1) necessary for
HIV-1 replication. In addition, bDLE was discovered to
act through all viral cycle stages to protect cells from HIV-
1 infection for hours without affecting the HIV membrane.
Based on our results obtained above, bDLE should be
further studied to determine its potential use as a thera-
peutic agent in HIV-1 infection, especially due to its long-
lasting cell protection against HIV-1 infection and lack of
negative side effects.
Methods
Reagents, cells and HIV-1 isolates
The following reagents were obtained through the AIDS
Research and Reference Reagent Program (NIH): HeLa-
CD4-LTR-b-gal cells from Dr. Michael Emerman; HL2/3
cells from Dr. Barbara K. Felber and Dr. George N. Pavla-
kis; HIV-1IIIB, fusion inhibitor T-20, integrase inhibitor
118-D-24 and protease inhibitor Amprenavir from Dr.
Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert
Gallo. UC781, a no nucleoside reverse-transcriptase inhi-
bitor (NNRTI), was kindly donated by Dr. Gadi Borkow.
The bDLE used in our study was produced by the
Laboratory of Immunology and Virology at the Universi-
dad Autonoma de Nuevo Leon, Mexico, following a mod-
ified process described by Lawrence et al. [9]. The bDLE
was lyophilized, tested for endogenous pyrogens using
the Limulus amebocyte lysate assay (MP Biomedicals,
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Inc.), and determined to be free of bacterial contamina-
tion by culturing in media and in vivo mice inoculations.
The bDLE obtained from 15 × 108 leukocytes was
defined as one unit (1 Unit)[37].
Cytotoxicity Assays
A stock solution of bDLE was diluted two-fold diluted in
growth medium and subsequently added into wells con-
taining 5 × 104 HeLa-CD4-LTR-b-gal cells. Microtiter
plates were incubated at 37°C in a 5% CO2 air humidified
atmosphere for 24 hours. Assessments of cell viability
were carried out using a CellTiter-Glo® Luminescent Cell
Viability Assay (Promega). Cytotoxicity was evaluated
based on the percentage cell survival relative to the result
obtained in the absence of any compound.
HIV-1 Infection Inhibition Assays
Serial two-fold dilutions of bDLE were mixed with 105
TCID50 of HIV-1IIIB and added to the wells containing 5 ×
104 HeLa-CD4-LTR-b-gal cells with a multiplicity of infec-
tion (MOI) of 0.2 - 0.5. HIV-1 infection was assessed after
24 hours of incubation by quantifying the activity of the b-
galactosidase produced after infection with the Beta-Glo
Assay System (Promega). The 50% inhibitory concentra-
tion (IC50) was defined according to the percentage of
infection inhibited relative to the positive control.
Virucidal Activity Assay
Serial two-fold dilutions of bDLE were added to HIV-1IIIB
(T tropic virus) and HIV-1Ba-L (M Tropic) cell-free virus.
After incubation for 5 min at room temperature, the mix-
tures were centrifuged three times at 10, 000 rpm, the
supernatant fluids removed, and the pellets washed three
times. The final pellets were resuspended in Dulbecco’s
Modified Eagle Medium (DMEM) and placed into 96-well
plates with HeLa-CD4-LTR-b-gal cells. The cells were
incubated in a 5% CO2 humidified incubator at 37°C for
24 h. Assessment of HIV-1 infection was made with the
Beta-Glo Assay System. The percentage of residual infec-
tivity after bDLE treatment was then calculated with
respect to the positive control of untreated virus.
Cell-based Fusion Assay
HeLa-derived HL2/3 cells (Env cells), which express the
HIV-1HXB2 Env, Tat, Gag, Rev, and Nef proteins, were
co-cultured with HeLa-CD4-LTR-b-gal cells (CD4 cells)
at a 1:1 cell density ratio (5 × 104 cells/well each) for 24 h
in the absence or presence of two-fold dilutions of bDLE,
UC781, and T-20 in order to examine whether the com-
pounds interfered with the binding process of HIV-1 Env
and the CD4 receptor. Also, both HeLa-CD4-LTR-b-gal
and HL2/3 cells were exposed to the aforementioned
compounds for only 30 minutes and then washed twice
to eliminate residual compound before co-cultivating
with the other cell line. Upon fusion of both cell lines,
the Tat protein from HL2/3 cells activated b-galactosi-
dase (b-gal) indicator gene expression in HeLa-CD4-
LTR-b-gal cells [41]. b-gal activity was quantified with
the Beta-Glo Assay System (Promega). The percentage of
inhibition of HL2/3-HeLa CD4 cell fusion was calculated
with respect to the positive control of untreated cells.
Time of Addition Experiments
HeLa-CD4-LTR-b-gal cells were infected with 105 TCID50
of HIV-1IIIB cell-free virus with a 0.2-0.5 MOI. bDLE (2
IU), T-20 (100 μM), UC781 (70 nM), 118-D-24 (120 μM)
and Amprenavir (0.1 mM) were then added upon HIV-1
inoculation (time zero) or at various time points post-
inoculation. The reference compounds were added at a
concentration several times their EC50 for infectivity of
HIV-1IIIB. Infection inhibition was quantified after 24 h by
measuring b-gal activity with the Beta-Glo Assay System.
Cell Protection Assays
HeLa-CD4-LTR-b-gal cells were incubated with bDLE
(2 Units) for 30 minutes and subsequently washed with
PBS three times. Then, the cells were exposed to 105
TCID50 of HIV-1IIIB cell-free virus with a 0.2-0.5 MOI
for different times (1, 5, 7, 10, 24 and 48 h). Infection
inhibition was quantified after 24 h by measuring b-gal
activity with the Beta-Glo Assay System.
Statistical analysis
Graphs were done with SigmaPlot 10.0 software and the
values shown are means ± standard deviations from
three separate experiments, each of which was carried
out in duplicate. Cytotoxicity and inhibition assessment
graphs are linear regression curves done with SigmaPlot
10.0 software.
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